antagonist psb 1115 Search Results


gw 6471  (Bio-Techne corporation)
95
Bio-Techne corporation gw 6471
Gw 6471, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antagonist+psb+1115/pm32142797-111-84-92?v=Bio-Techne+corporation
Average 95 stars, based on 1 article reviews
gw 6471 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
a2b antagonists  (Tocris)
95
Tocris a2b antagonists
(A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and <t>antagonists</t> to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, <t>A2b</t> receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from <t>d7-d21,</t> with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists <t>(1mg/kg,</t> i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.
A2b Antagonists, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antagonist+psb+1115/pmc09311231-497-80-90?v=Tocris
Average 95 stars, based on 1 article reviews
a2b antagonists - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
a2bar antagonist psb1115  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology a2bar antagonist psb1115
(A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and <t>antagonists</t> to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, <t>A2b</t> receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from <t>d7-d21,</t> with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists <t>(1mg/kg,</t> i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.
A2bar Antagonist Psb1115, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antagonist+psb+1115/pmc07253199-193-8-11?v=Santa+Cruz+Biotechnology
Average 90 stars, based on 1 article reviews
a2bar antagonist psb1115 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
a 2b r antagonist psb1115  (Tocris)
99
Tocris a 2b r antagonist psb1115
(A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and <t>antagonists</t> to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, <t>A2b</t> receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from <t>d7-d21,</t> with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists <t>(1mg/kg,</t> i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.
A 2b R Antagonist Psb1115, supplied by Tocris, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antagonist+psb+1115/pmc03884531-51-15-25?v=Tocris
Average 99 stars, based on 1 article reviews
a 2b r antagonist psb1115 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
selective a2b antagonists psb-53  (CEREP Inc)
90
CEREP Inc selective a2b antagonists psb-53
(A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and <t>antagonists</t> to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, <t>A2b</t> receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from <t>d7-d21,</t> with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists <t>(1mg/kg,</t> i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.
Selective A2b Antagonists Psb 53, supplied by CEREP Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antagonist+psb+1115/pm14563788-44-3-20?v=CEREP+Inc
Average 90 stars, based on 1 article reviews
selective a2b antagonists psb-53 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


(A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and antagonists to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, A2b receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from d7-d21, with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists (1mg/kg, i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.

Journal: Science translational medicine

Article Title: Metabolic adaptations of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

doi: 10.1126/scitranslmed.abg8402

Figure Lengend Snippet: (A) Cumulative data of the fold change in human healthy donor CD8+ T cell proliferation stimulated with anti-CD3/CD28 beads in the presence of the indicated combinations of NAD and antagonists to A2BR (PSB 1115), A2AR (SCH 58261), P2XR (oATP), P2X1R (NF 449), P2X3R (NF 110), A1R (PSB 36), P2X4R (5-BDBD) and P2Y1R (MRS 2279) respectively. In all box charts, the median and min-max of the values are presented; *P < 0.05, **P < 0.01, ***P < 0.001,****P < 0.0001. Wilcoxon and one-way ANOVA tests. (B) Survival data of IE9mp1-mIDO1 tumor-bearing mice treated with EPA, A2a, A2b receptor antagonist, or combination of EPA, A2a, and A2b receptor antagonist (n= 5 animals per group). Mice were treated by oral gavage with 300mg/kg EPA in 200μl 0.5% methylcellulose, i.p. injection 5 days on and two days off from d7-d21, with or without (i) NAMPT inhibitor FK866 (500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); and (ii) with or without A2a, A2b or A2a/A2b antagonists (1mg/kg, i.p. 5 days on two days off from d7-d21). *, P<0.05 compared to vehicle. Statistical analysis was calculated using a log-rank analysis. (C). Heatmap representing the Log2FC of core set genes of immune pathways that are significantly differentially expressed (FDR < 0.05) in the treatment groups compared with the vehicle group of mice. Blue and red indicate down- and up-regulation, respectively.

Article Snippet: C57BL/6 mice were challenged intraperitoneally (i.p.) with 1×10 7 IE9mp1-mIDO1 or IE9mp1-Empty-Vector tumor cells in a final volume of 500μl Dulbecco’s PBS (Corning Cellgro®) and treated by oral gavage with 300mg/kg IDO1 inhibitor INCB023843 (Incyte Corp.) in 200ul 0.5% methylcellulose, i.p. injection 5 days on and two days off from d7-d21, with or without (i) NAMPT inhibitor FK866 (Sigma-Aldrich, 500 μg per mouse i.p.) once every week for 3 weeks (on day 13, 20, 27); (ii) purinergic receptor A2a or A2b antagonists (Sch 58261 from Sigma-Aldrich or PSB 1115 from Tocris Bioscience, 1mg/kg, i.p. 5 days on two days off from d7-d21).

Techniques: Injection